Updates are available Correction dated 2024-04-01
Click to view Correction: https://doi.org/10.1007/s10072-024-07497-6
-
Authors
Panzavolta, Andrea
Cerami, Chiara https://orcid.org/0000-0003-1974-3421
Caffarra, Paolo
De Vita, Dalila
Dodich, Alessandra
Fonti, Cristina
L’Abbate, Federica
Laganà, Valentina
Lavorgna, Luigi
Marra, Camillo
Papagno, Costanza
Pellegrini, Francesca Ferrari
Stracciari, Andrea
Trojano, Luigi
Iaquinta, Tiziana
Ravizza, Alice
Sternini, Federico
Pandolfi, Roberta
Sanzone, Sveva
Calore, Monica
Cappa, Stefano F.
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 12 February 2024
First Online: 21 February 2024
Change Date: 1 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10072-024-07497-6
Declarations
:
: This study required the involvement of professional figures, who provided informed consent to the publication.
: Monica Calore and Sveva Sanzone are employees of Biogen Italia, and they may hold stock. Roberta Pandolfi is a former employee of Biogen and may hold stock. Alice Ravizza is the CEO and majority shareholder of InsideAI, and Federico Sternini is an employee and shareholder of InsideAI. Tiziana Iaquinta is an employee of Xenia Reply. Stefano Cappa has received speaker honoraria from Biogen, Roche and Nutricia and has been member of the Scientific Advisory Board of Brain Control. Camillo Marra has been granted for speech and consultancy by Biogen Eisai, Novo Nordisk, Angelini, PIAM, Eli Lilly. Andrea Panzavolta, Chiara Cerami, Paolo Caffarra, Dalila De Vita, Alessandra Dodich, Federica L’Abbate, Valentina Laganà, Luigi Lavorgna, Costanza Papagno, Francesca Ferrari Pellegrini, Andrea Stracciari and Luigi Trojano have nothing to declare.
